Kamada Ltd. (NASDAQ:KMDA) Short Interest Update

Kamada Ltd. (NASDAQ:KMDA) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totaling 76,618 shares, a growth of 69.3% from the November 30th total of 45,256 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average trading volume of 124,838 shares, the short-interest ratio is presently 0.6 days. Based on an average trading volume of 124,838 shares, the short-interest ratio is presently 0.6 days. Approximately 0.2% of the shares of the company are sold short.

Kamada Price Performance

Shares of KMDA stock traded down $0.02 during trading hours on Friday, reaching $7.07. 54,309 shares of the company traded hands, compared to its average volume of 99,476. The firm has a 50-day moving average price of $6.94 and a 200 day moving average price of $7.12. The company has a market cap of $406.60 million, a P/E ratio of 19.64, a P/E/G ratio of 0.75 and a beta of 0.92. Kamada has a 12-month low of $5.54 and a 12-month high of $9.15.

Kamada (NASDAQ:KMDA) last released its earnings results on Monday, November 10th. The biotechnology company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.01). The firm had revenue of $47.01 million during the quarter, compared to analysts’ expectations of $154.21 million. Kamada had a return on equity of 7.89% and a net margin of 11.70%. Sell-side analysts predict that Kamada will post 0.23 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on KMDA. Wall Street Zen upgraded shares of Kamada from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 13th. Weiss Ratings reissued a “buy (b-)” rating on shares of Kamada in a report on Wednesday, October 8th. Finally, HC Wainwright raised their price target on Kamada from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, Kamada presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.00.

Institutional Trading of Kamada

Several institutional investors and hedge funds have recently added to or reduced their stakes in KMDA. ARK Investment Management LLC purchased a new position in shares of Kamada in the 2nd quarter worth $1,972,000. Goldman Sachs Group Inc. purchased a new stake in shares of Kamada during the 1st quarter valued at about $497,000. Huntleigh Advisors Inc. lifted its holdings in shares of Kamada by 3.9% in the 2nd quarter. Huntleigh Advisors Inc. now owns 135,776 shares of the biotechnology company’s stock valued at $1,052,000 after acquiring an additional 5,151 shares during the last quarter. Acadian Asset Management LLC grew its position in Kamada by 3.1% in the second quarter. Acadian Asset Management LLC now owns 263,556 shares of the biotechnology company’s stock worth $2,053,000 after acquiring an additional 7,925 shares in the last quarter. Finally, Trexquant Investment LP purchased a new position in Kamada in the first quarter worth about $82,000. Institutional investors own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.